Abstract Library

#1651 Renal Neuroendocrine Tumors (rNETs): A Single-Center Experience.

Introduction: rNETs are rare tumors and little is known about their natural history.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Halfdanarson T

Authors: Westin G, Ingimarsson J, Scales J, Hobday T, Halfdanarson T,

Keywords: Renal, Kidney, NET, Carcinoid,

#1193 Health-Related Quality of Life (HRQoL) with Lanreotide Autogel (LAN) 120 mg in Patients with Enteropancreatic (EP-) NETs: Post Hoc Analyses from the CLARINET Study

Introduction: In CLARINET, favourable efficacy and safety with LAN in metastatic EP-NETs was associated with stable HRQoL outcomes.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Caplin M, Pavel M, Cwikla J, Phan A, Raderer M,

Keywords: lanreotide, quality of life,

#358 Enhanced Combined 177Lu-DOTATATE and 90Y-DOTATATE Treatment of Patients with Metastatic Neuroendocrine Tumors Refractory to Conventional Therapy: An Ongoing Study.

Introduction: Neuroendocrine tumors (NETs) over-express somatostatin receptors (SRs) and the efficacy of peptide receptor radionuclide therapy (PRRT) with somatostatin analogues labeled with high activities of ß-emitting radioisotopes have been reported.

Conference:

Presenting Author:

Authors: Mallia A, Seregni E, Maccauro M, Chiesa C, Coliva A,

Keywords: Neuroendocrine tumors,peptide receptor radionuclide therapy. Study is partially supported by a grant from the Min.of Health (5 per mille) and Italian Association of Cancer (AIRC).,